Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.
Saved in:
| Title: | Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. |
|---|---|
| Authors: | Loria R; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Vici P; Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Di Lisa FS; Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Medical Oncology A, Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Umberto I University Hospital, University Sapienza, Rome, Italy., Soddu S; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Maugeri-Saccà M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Bon G; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Jun 23; Vol. 12, pp. 877380. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35814399 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Loria+R%22">Loria R</searchLink>; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Vici+P%22">Vici P</searchLink>; Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Di+Lisa+FS%22">Di Lisa FS</searchLink>; Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Medical Oncology A, Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Umberto I University Hospital, University Sapienza, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Soddu+S%22">Soddu S</searchLink>; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Maugeri-Saccà+M%22">Maugeri-Saccà M</searchLink>; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Bon+G%22">Bon G</searchLink>; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Jun 23; Vol. 12, pp. 877380. <i>Date of Electronic Publication: </i>2022 Jun 23 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35814399 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2022.877380 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 877380 Titles: – TitleFull: Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Loria R – PersonEntity: Name: NameFull: Vici P – PersonEntity: Name: NameFull: Di Lisa FS – PersonEntity: Name: NameFull: Soddu S – PersonEntity: Name: NameFull: Maugeri-Saccà M – PersonEntity: Name: NameFull: Bon G IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 06 Text: 2022 Jun 23 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 12 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |